Regulation of CYP2C19 expression by estrogen receptor α: Implications for estrogen-dependent inhibition of drug metabolism

Molecular Pharmacology

Volumn 78, Issue 5, 2010, Pages 886-894

  Mwinyi, Jessica ^a   Cavaco, Isa ^a,b   Pedersen, Rasmus Steen ^a   Persson, Anna ^a   Burkhardt, Sabrina ^a   Mkrtchian, Souren ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ETHINYLESTRADIOL; LUCIFERASE;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; CELLS, CULTURED; CONTRACEPTIVES, ORAL, HORMONAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ETHINYL ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION;

EID: 77958122503     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065540     Document Type: Article

References (33)

1. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, and Hall SD (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67-74. (Pubitemid 34117741)
2. Benowitz NL, Lessov-Schlaggar CN, Swan GE, and Jacob P 3rd (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480-488.
3. Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, Newbold RR, and Korach KS (1997) Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog 19:236-242.
4. Desta Z, Zhao X, Shin JG, and Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958. (Pubitemid 35168437)
5. Dignam JD, Lebovitz RM, and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
6. Driscoll MD, Sathya G, Muyan M, Klinge CM, Hilf R, and Bambara RA (1998) Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 273:29321-29330. (Pubitemid 28509931)
7. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, and Matthias P (2001) Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J Biol Chem 276:35444-35449.
8. Hägg S, Spigset O, and Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173. (Pubitemid 32216067)
9. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, and Nakajima M (2007) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935-1941. (Pubitemid 47481589)
10. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, and Korach KS (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658-4662.
11. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, and Korach KS (1996) Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137:1735-1744. (Pubitemid 26133949)
12. Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637-639.
13. Ingelman-Sundberg M, Sim SC, Gomez A, and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. (Pubitemid 350116943)
14. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Winter S, et al. (2009) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 115:391-396.
15. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, and Brockmöller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473. (Pubitemid 38903502)
16. Klose TS, Blaisdell JA, and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
17. Klotz U (2009) Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol 65:1-2.
18. Laine K, Tybring G, and Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68:151-159. (Pubitemid 30659170)
19. Laine K, Yasar U, Widén J, and Tybring G (2003) A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81. (Pubitemid 36981412)
20. Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, and Kivistö KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13:565-575. (Pubitemid 37168057)
21. McDevitt MA, Glidewell-Kenney C, Jimenez MA, Ahearn PC, Weiss J, Jameson JL, and Levine JE (2008) New insights into the classical and non-classical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice. Mol Cell Endocrinol 290:24-30.
22. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, and Tamaoki T (1991) A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol 11:5885-5893. (Pubitemid 21895356)
23. Palovaara S, Tybring G, and Laine K (2003) The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 56:232-237. (Pubitemid 36981441)
24. Safe S, Kim K, and Kim K (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41:263-275.
25. Sandberg M, Johansson I, Christensen M, Rane A, and Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32:484-489. (Pubitemid 38535025)
26. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, and Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193. (Pubitemid 350232249)
27. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, et al. (2005) Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45:1413-1421. (Pubitemid 41642445)
28. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman- SundbergM(2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113. (Pubitemid 43069582)
29. Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, and Jonkman JH (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55:177-184. (Pubitemid 29244644)
30. van de Stolpe A, Slycke AJ, Reinders MO, Zomer AW, Goodenough S, Behl C, Seasholtz AF, and van der Saag PT (2004) Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ERalpha and ERbeta. Mol Endocrinol 18:2908-2923. (Pubitemid 39577915)
31. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988. (Pubitemid 37221681)
32. Wu M, Chen S, and Wu X (2006) Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients. Med Sci Monit 12:BR174-BR178.
33. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, and Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133-157. (Pubitemid 46193058)